Both in Pharmaceuticals
Ocular Therapeutix vs Zenas BioPharma
Over the past year OCUL returned −37.2% and ZBIO returned +30.1%; their daily moves had a correlation of 0.15.
OCUL −37.2% ZBIO +30.1%Growth of $1, one year, split-adjusted
| Metric | OCUL | ZBIO |
|---|---|---|
| Price | $7.87 | $26.76 |
| Market cap | $1.73B | $1.74B |
| Today | +2.81% | −2.87% |
| 1 month | −24.0% | −14.4% |
| 6 months | +6.4% | +46.8% |
| Year to date | −35.2% | −26.3% |
| 1 year | −37.2% | +33.2% |
| Revenue growth (YoY) | +0.1% | — |
| Gross margin | 85.1% | 100.0% |
| Net margin | −584.5% | −11145.6% |
| P/E (TTM) | — | — |
| Price / sales | 33.2× | 1,744.1× |
| Net cash | $525.8M | $346.1M |
| Dividend yield | — | — |
| Volatility (60d) | 71.7% | 54.4% |
| Short % of float | 15.7% | 38.1% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).